Table 6.
Results of studies reporting on the prognostic value of end-of-treatment FDG-PET
| Study (year) | Criteria for positivity | Follow-up time in months (range) | No. of FDG-PET negative/positive patients | Number of relapses/progressions/events | PFS | Median/mean PFS (months) | Hazard ratio PFS | Deaths | OS | Median/mean OS (months) | Hazard ratio OS |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Lu et al. (2014) [6] | Cheson/Barrington 2014 [3]/Deauville 4 + 5 | 42.2a (7.8–103.8) | Negative, 39 (83.0 %) Positive, 8 (17.0 %) |
NR | 3-year PFS Negative, 72 % Positive, 30 % |
Negative, 74.4 Positive, 38.2 (P = 0.083)b |
2.6 (95 % CI, 0.7–9.1) (P = 0.083) | NR | 3-year OS: Negative, 96 % Positive, 60 % |
Negative, 95.2 Positive, 45.0 (P < 0.001) |
10.8 (95 % CI, 2.8–41.6, P < 0.001) |
| Luminari et al. (2014) [7] | NR | 34a (7–66) | Negative, 153 (75.7 %) Positive, 49 (24.3 %) |
NR | 3-year PFS: Negative, 66 % Positive, 35 % (P < 0.001) |
NR | PFS, 2.59, 95 % CI, 1.59–4.24, P < 0.001) | Negative, 3/153 (2.0 %) Positive, 3/49 (6.1 %) | NR | NR | NR |
| Zinzani et al. (2013) [8] | NR | 48a (6–145) | NR | NR | 5-year PFS: Negative, 75.5 % Positive, 42 % (P = 0.002) |
NR | NR | NR | NR | NR | NR |
| Dupuis et al. [9] (2012) | Cheson/Barrington 2014 [3]/Deauville 4 + 5 | 23b | Negative 83/106 (78.3 %) Positive, 23/106 (21.7 %) |
NR | 2-year PFS: Negative, 87 % Positive, 51 % (P < 0.001) |
NR | NR | NR | 2-year OS, Negative, 100 % Positive, 88 % (P = 0.0128) |
NR | NR |
| Trotman et al. 2011 [10] | NR | 42b (6–57) | Negative, 90 (73.8 %) Positive, 32 (26.2 %) |
NR | 42-month PFS: Negative, 70.7 % Positive, 32.9 % (P < 0.001) |
Negative, not reached Positive, 20.5a |
3.3 (95 % CI, 1.9–5.9) | Negative, 3/90 (3.3 %) Positive, 7/32 (21.8 %) |
42-month OS: Negative, 96.5 % Positive, 78.5 % (P = 0.0011) |
NR | 7.0 (95 % CI, 1.8–27.0, P = 0.0011) |
| Le Dortz et al. [11] (2010) | Cheson/Juweid 2007 [2]/>MBP | 36a (24–50) | Negative, 32/45 (71.1 %) Positive, 13/45 (28.9 %) |
Negative, 5/32 (15.6 %) Positive, 11/13 (84.6 %) (5× second-line treatment initiation, 6× progression) |
NR | Negative, 48 Positive, 17.2 (P < 0.0001) |
NR | NR | NR | NR | NR |
| Bishu et al. [12] (2007) | Cheson/Juweid 2007 [2]/>MBP | 28b (6–59) | Negative, 14/16 (87.5 %) Positive, 2/16 (12.5 %) |
Negative, 1/14 (7 %) Positive, 2/2 (100 %) |
NR | Negative, 29.5 months Positive, 5.8b |
NR | NR | NR | NR | NR |
| Zinzani et al. [13] (2007) | NR | 25a (20–34) | Negative, 34/45 (75.6 %) Positive, 11/45 (24.4 %) |
Negative, 2/34 (5.9 %) Positive, 10/11 (90.9 %) |
NR | NR | NR | NR | NR | NR | NR |
CI confidence interval, MBP mediastinal blood pool, NR not reported, PFS progression-free survival, OS overall survival
aMedian
bMean